01 / Research

Filing-backed research notes

Daily analysis of Indian market events grounded in real corporate filings. Every claim is backed by what companies actually said in their annual reports and quarterly results.


Policy Impact 3 April 2026

India Waives Customs Duty on Petrochemicals: 5 Stocks That Stand to Gain

The government has exempted customs duty on critical petrochemical products till June 30 amid the West Asia crisis. Here are five NSE-listed companies whose margins could improve.

FILATEXPOLYPLEXDEEPAKNTRSTYRENIXAPOLLOTYRE
Deep Dive 2 April 2026

Everyone's Watching the War — But China's Biologics Push Is the Bigger Threat to Indian Pharma

While West Asia dominates headlines, China is quietly pulling ahead in biologics manufacturing. We dig into filings to see which Indian pharma companies are best prepared and which are falling behind.

BIOCONZYDUSLIFEALKEMPPLPHARMASUNPHARMAGLAND
Sector Insight 1 April 2026

Headline Says Tariff Pain for Textiles — The Real Winners Are in Electronics Manufacturing

US tariffs squeeze Indian garment exporters, but new trade deals with EU and UK are opening doors for electronics manufacturers and medical device makers. We dig into the filings.

CELEBRITYKPRMILLDIXONEPACKAMBERPOLYMED
Opportunity 31 March 2026

Oil Spikes on Hormuz Crisis — 5 Renewable Energy Stocks That Actually Benefit

As crude oil surges on Iran-Hormuz tensions and the Sensex crashes 1,700 points, renewable energy and solar stocks with strong order books stand to gain from accelerated energy transition.

PREMIERENESUZLONADANIGREENSWSOLARINOXWINDAJANTPHARMMRPL
Deep Dive 30 March 2026

Centre Eyes Essential Commodities Act for Bulk Drugs — Who Gets Hurt, Who Quietly Wins

The government is considering invoking the Essential Commodities Act to regulate bulk drug prices. We dig into filings to find which API makers face margin pressure and which formulation companies could benefit from cheaper inputs.

DIVISLABSOLARANEULANDLABSUNPHARMAAUROPHARMACIPLAGLAND
Impact Analysis 27 March 2026

West Asia Crisis Sends Crude Soaring — Five Companies Where the Pain Shows Up in Filings

The West Asia conflict is pushing crude oil higher. We dug into quarterly filings of IndiGo, HINDPETRO, BPCL, Asian Paints, and Oil India to see who gets hurt — and who quietly benefits.

INDIGOHINDPETROBPCLASIANPAINTOIL
Policy Impact 26 March 2026

US Tariffs on India Reset to 15% — Five Companies With the Most at Stake

A US Supreme Court ruling rolled back Trump's 50% tariffs on India to 15%. We dug into corporate filings to find which NSE-listed exporters have the most US revenue exposure — and the most to gain.

SUNPHARMADRREDDYCIPLAMOTHERSONVAIBHAVGBL
Policy Impact 25 March 2026

US Slashes Textile Tariff to 18%: Five Indian Exporters Set to Gain

The India-US tariff reset has cut duties on Indian textiles to 18%. We dug into filings of Welspun Living, Trident, Indo Count and others to find who benefits most.

WELSPUNLIVTRIDENTICILFILATEXRSWM
Policy Impact 24 March 2026

India Cracks Down on Unauthorized GLP-1 Drugs — Five Companies With Approved Pipelines Stand to Win

DCGI intensifies enforcement against unauthorized GLP-1 weight-loss drugs. Filing evidence shows these five companies are building legitimate semaglutide pipelines and delivery devices.

NATCOPHARMCIPLAEMCURESHAILYALKEM
Policy Impact 23 March 2026

India's Proposed Steel Import Tariff: 5 Domestic Producers Set to Benefit

India is considering an 11-12% tariff on select steel imports for 3 years. We dug into quarterly filings of JSW Steel, Tata Steel, Jindal Steel, SAIL, and Jindal Stainless to find who benefits most.

JSWSTEELTATASTEELJINDALSTELSAILJSL
Deep Dive 20 March 2026

Accenture's Cautious Q3 Outlook Rattled IT Stocks — But Five Indian IT Companies' Own Filings Tell a Different Story

Accenture guided Q3 revenue below estimates, but Infosys, HCL Tech, Tech Mahindra, Mphasis, and Hexaware filings show deal wins, margin expansion, and AI-driven growth that the market is overlooking.

INFYHCLTECHTECHMMPHASISHEXT
Policy Impact 19 March 2026

US Tariffs Reset to 15%: Six Indian Exporters With the Most to Gain

The US Supreme Court struck down Trump's elevated tariffs, resetting duties on Indian goods to 15%. We dig into filings to find which NSE-listed exporters stand to benefit most.

WELSPUNLIVSUNPHARMAGLANDGOLDIAMRAYMONDLSLTRIDENT
Opportunity 18 March 2026

US Tariffs Reset to 15%: Five Indian Exporters With the Most to Gain

The US Supreme Court ruling resetting tariffs to 15% gives Indian textile and pharma exporters a reprieve. We dig into filings to find who benefits most.

WELSPUNLIVSUNPHARMADRREDDYICILTRIDENT
Impact Analysis 17 March 2026

Oil Above $100: Which Indian Companies Face the Biggest Margin Squeeze — and Who Quietly Benefits

With Brent crude above $100 amid the Iran conflict, we dig into corporate filings to find which Indian companies face margin pressure from surging oil — and which upstream and energy names stand to gain.

INDIGOASIANPAINTHINDPETROMRFONGCOILCOALINDIA
Impact Analysis 16 March 2026

US Launches Section 301 Probe Into India: These Export-Heavy Stocks Face the Most Heat

The US has launched a Section 301 trade investigation targeting India. We dug into filings of pharma, auto component, and aluminium exporters to find who is most exposed.

SUNPHARMADRREDDYALKEMGLANDSUNDRMFASTSCHAEFFLERHINDALCO